Perioperative Clinical Investigation Of Serum Vascular Endothelial Growth Factors Level In Patients With Colorectal Carcinoma And Their Significance

Objective To determine the serum level of vascular endothelial growth factors (VEGF) in colorectal carcinoma and the relationship between serum VEGF and clinical pathological stage in colorectal carcinoma patients before operation and study whether the serum VEGF level can be a tumor marker of diagnosis and the curative effect and prognosis of colorectal carcinoma and the unite detection significance of the serum VEGF and CEA and CA19-9 in the diagnosis and accompanying of colorectal carcinoma. Methods The serum VEGF was determined by ELISA and CEA and CA19-9 was determined by radio-immunity method. Results The serum VEGF and CEA and CA19-9 level of 39 colorectal carcinoma patients before and after the operation were analyzed. There were significant difference among before operation, after operation 3d, 7d and 10d (p<0.05). Patients with Dukes stage C and D disease had significantly (p<0.05) higher levels of VEGF than patients with Dukes stage A and B. There were no significant correlation among gender, age with serum VEGF (p>0.05). Patients with lymphode metastasis had significantly (p<0.05) higher levels of VEGF than patients without lymphode metastasis. Patients with organ metastasis had significantly (p<0.05) higher levels of VEGF than patients without organ metastasis. The serum VEGF level was significantly lower in well-moderate differentiated carcinoma than in moderate-poorly differentiated one. The positive rate were 35.9% (VEGF) and 43.6% (CEA) and 38.5% (CA19-9) and 69.2% (one were positive among VEGF, CEA and CA19-9), the positive rate were elevated significantly. Conclusions VEGF can be a tumor marker for diagnosis and stage and prognosis of colorectal carcinoma. The positive rate could be elevated significantly in the patients with colorectal carcinoma when the serum VEGF and CEA and CA19-9 were simultaneously detected.